80 mg/day of Silexan (oral) for anxiety.
⏱ 3 min read
Lavender is Lavandula angustifolia, a Mediterranean member of the mint family whose extracts and essential oil have been used for centuries in European medicine and perfumery; in the last two decades, a specific formulation of standardized oral lavender oil (Silexan, marketed as the medicine Lasea in Germany and other European countries) has reached a notable clinical profile, with data from high-quality randomized controlled trials showing anxiolytic efficacy comparable to benzodiazepines at standard doses in generalized anxiety disorder, one of the few herbal therapies with clinical support at this level for clinical anxiety.
Lavender oil contains linalool and linalyl acetate as its main volatile compounds, along with other minor monoterpenes with documented activity on serotonergic and GABAergic receptors and neuronal calcium channels; the Silexan formulation specifically is an oil standardized to the exact concentration of its active components, encapsulated for oral release with predictable pharmacokinetics, a pharmaceutical-technology feature that distinguishes it significantly from generic or aromatherapy preparations.
The indication with the strongest clinical support is generalized anxiety disorder in adults: several randomized controlled trials with placebo and active comparators (lorazepam, paroxetine) have documented significant efficacy of Silexan at 80-160 mg/day for 6-10 weeks, with effect sizes comparable to those of lorazepam at 0.5 mg/day, without the sedative effects, dependence, or withdrawal syndrome characteristic of benzodiazepines, and comparable to those of the antidepressant paroxetine without the sexual or weight-gain side effects of SSRIs.
A meta-analysis published in 2019 including 5 randomized trials confirmed the significant and consistent efficacy of Silexan in anxiety, with a tolerability profile favorable compared with standard drug options; these data position the product as a reasonable first-line option in mild to moderate generalized anxiety, especially in people who prefer to avoid benzodiazepines or SSRIs or who have contraindications to them.
In mild insomnia, especially when associated with anticipatory anxiety, lavender in aromatherapy applications (diffused oil or oil applied topically to a pillow) and in oral formulations has shown modest improvements in subjective sleep quality; the effects are quantitatively smaller than those of pharmacological hypnotics but sufficient for many people with mild insomnia.
Applied topically (oil diluted in a carrier oil) or inhaled (diffusers, application to a pillow), lavender has modest anxiolytic effects documented in small studies, with clinical support for complementary use in acute stress, perioperative anticipatory anxiety (before procedures), and as a sleep aid; its clinical potency is clearly lower than that of standardized oral oil, but its ease of use and tolerability profile make lavender aromatherapy an accessible and reasonable option as an adjunct.
For generalized anxiety, Silexan at 80-160 mg/day as a single morning dose for 6-10 weeks as a clinical trial; the effect is gradual and takes 2-4 weeks for an initial assessment; for aromatherapy use, apply diluted essential oil (1-3 percent in a carrier oil) to the wrists, temples, or a pillow, or diffuse it in the room for 30-60 minutes before sleep or anxiety-provoking situations.
Generally very well tolerated in oral use with Silexan; the most common adverse effects are lavender-flavored burping (typically transient and mild), occasionally mild digestive discomfort or headache; it does not produce significant sedation, dependence, or withdrawal syndrome, an important advantage over benzodiazepines; people with allergic asthma may have hypersensitivity reactions from inhalation; direct undiluted topical application can cause contact dermatitis; people with epilepsy should be cautious because some isolated cases suggest a possible lowering of the seizure threshold at high doses (preliminary data); it is discouraged in pregnancy as a precaution; during breastfeeding, isolated cases of gynecomastia have been described in prepubertal children repeatedly exposed to topical products containing lavender and tea tree (attributed to weak estrogenic activity), so moderation is advisable with topical use in young children; the essential oil should not be ingested without a specific formulation; commercial aromatherapy products vary enormously in quality and purity, and it is advisable to choose essential oils with third-party-certified composition analysis.
Information, not medical advice. Scientific evidence reflects the quality of the studies.